Coronary Heart DiseasePhase 3NCT00658515
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
A Phase 3 study testing Dalcetrapib (RO4607381) and Evidence-based medical care for Acute Coronary Syndrome in people with Coronary Heart Disease, run by Hoffmann-La Roche at 1,089 sites in 29 countries.
Trial summary
This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of the drug. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Coronary Heart Disease
- What is being tested?
- Dalcetrapib (RO4607381) and Evidence-based medical care for Acute Coronary Syndrome
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15,871 participants
- Where
- 1,089 sitesin 29 countries
- Study dates
- Apr 2008to Sep 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adult patients, >=45 years of age;
- recently hospitalized for ACS;
- clinically stable;
- receiving evidence-based medical and dietary management of dyslipidemia.
Who cannot join
- uncontrolled diabetes;
- clinically unstable;
- severe anemia;
- uncontrolled hypertension;
- concomitant treatment with any other drug raising HDL-C (eg niacin, fibrates).
Trial locations and contacts
1,089 sites in 29 countries.
876 sites in 29 countries
United States300 sites
Study site
Abington, Pennsylvania, 19001
Study site
Aiken, South Carolina, 29801
Study site
Akron, Ohio, 44304
Study site
Akron, Ohio, 44307
Study site
Albany, New York, 12211
Study site
Albuquerque, New Mexico, 87131
Study site
Alexandria, Louisiana, 71301
Study site
Allentown, Pennsylvania, 18105
Study site
Alpena, Michigan, 49707
Study site
Altoona, Pennsylvania, 16602
Study site
Ames, Iowa, 50010
Study site
Anaheim, California, 92801
Study site
Anderson, Indiana, 46060
Study site
Ann Arbor, Michigan, 48105
Study site
Asheville, North Carolina, 28803
Study site
Athens, Ohio, 45701
Study site
Atlanta, Georgia, 30303
Study site
Atlanta, Georgia, 30308
Study site
Atlanta, Georgia, 30309
Study site
Atlanta, Georgia, 30312
Study site
Atlanta, Georgia, 30318
Study site
Atlanta, Georgia, 30322
Study site
Atlanta, Georgia, 30342
Study site
Aurora, Illinois, 60504
Study site
Austin, Texas, 78666
Study site
Austin, Texas, 78756
Study site
Aventura, Florida, 33180
Study site
Bakersfield, California, 93308
Study site
Baltimore, Maryland, 21201
Study site
Baltimore, Maryland, 21202
Study site
Baltimore, Maryland, 21218
Study site
Baltimore, Maryland, 21229
Study site
Baltimore, Maryland, 21237
Study site
Baltimore, Maryland, 21239
Study site
Bangor, Maine, 04401
Study site
Bannockburn, Illinois, 60015
Study site
Bartlesville, Oklahoma, 74006
Study site
Beaver, Pennsylvania, 15009
Study site
Bel Air, Maryland, 21014
Study site
Bellevue, Washington, 98004
Study site
Bellflower, California, 90706
Study site
Beloit, Wisconsin, 53511
Study site
Bend, Oregon, 97701
Study site
Beverly Hills, California, 90210
Study site
Biddeford, Maine, 04005
Study site
Billerica, Massachusetts, 01821
Study site
Billings, Montana, 59101
Study site
Birmingham, Alabama, 35213
Study site
Birmingham, Alabama, 35215
Study site
Birmingham, Alabama, 35235
Study site
Birmingham, Alabama, 35294
Study site
Bloomfield, Michigan, 48302
Study site
Boise, Idaho, 83712
Study site
Boston, Massachusetts, 02114
Study site
Boston, Massachusetts, 02215
Study site
Boynton Beach, Florida, 33472
Study site
Bridgeport, Connecticut, 06606
Study site
Bridgewater, New Jersey, 08807
Study site
Bristol, Tennessee, 37620
Study site
Brooklyn, New York, 11201
Study site
Brooklyn, New York, 11203
Study site
Brooklyn, New York, 11212
Study site
Brooklyn, New York, 11229
Study site
Bryn Mawr, Pennsylvania, 19010-3121
Study site
Buena Park, California, 90621
Study site
Buffalo, New York, 14203
Study site
Buffalo, New York, 14215
Study site
Burbank, California, 91505-4866
Study site
Burke, Virginia, 22015
Study site
Burlington, Wisconsin, 53105
Study site
Cadillac, Michigan, 49601
Study site
Camp Hill, Pennsylvania, 17011
Study site
Canton, Ohio, 44708
Study site
Carmichael, California, 95608
Study site
Cary, North Carolina, 27511
Study site
Centerville, Ohio, 45459
Study site
Chapel Hill, North Carolina, 27599
Study site
Charleston, South Carolina, 29406
Study site
Charleston, South Carolina, 29425
Study site
Charlotte, North Carolina, 28203
Study site
Charlotte, North Carolina, 28204
Study site
Charlottesville, Virginia, 22908
Study site
Chaska, Minnesota, 55318
Study site
Chicago, Illinois, 60616
Study site
Chipley, Florida, 32428
Study site
Cincinnati, Ohio, 45203-0542
Study site
Cincinnati, Ohio, 45219
Study site
Clarksburg, West Virginia, 26301
Study site
Clearwater, Florida, 33756
Study site
Clearwater, Florida, 33764
Study site
Cleveland, Ohio, 44195
Study site
Clifton, New Jersey, 07012
Study site
Colonial Heights, Virginia, 23834
Study site
Colorado Springs, Colorado, 80907
Study site
Colorado Springs, Colorado, 80909
Study site
Columbia, Maryland, 21044
Study site
Columbia, Missouri, 65201
Study site
Columbia, South Carolina, 29204
Study site
Columbus, Georgia, 31904
Study site
Columbus, Ohio, 43235
Study site
Concord, North Carolina, 28025
Study site
Corona, California, 92879
Study site
Costa Mesa, California, 92626
Study site
Council Bluffs, Iowa, 51501
Study site
Covington, Georgia, 30014
Study site
Crystal River, Florida, 34429
Study site
Dallas, Texas, 75216
Study site
Dallas, Texas, 75230
Study site
Dallas, Texas, 75231
Study site
Dallas, Texas, 75243
Study site
Dallas, Texas, 75390
Study site
Danbury, Connecticut, 06810
Study site
Danville, Virginia, 24541-4160
Study site
Danville, Virginia, 24541
Study site
Davenport, Iowa, 52803
Study site
Daytona Beach, Florida, 32114
Study site
Daytona Beach, Florida, 32117
Study site
Dearborn, Michigan, 48124
Study site
Decatur, Georgia, 30033
Study site
Deerfield Beach, Florida, 33442
Study site
Delray Beach, Florida, 33445
Study site
Delray Beach, Florida, 33484
Study site
Denver, Colorado, 80218
Study site
Denver, Colorado, 80220
Study site
Detroit, Michigan, 48221
Study site
Detroit, Michigan, 48235
Study site
Downingtown, Pennsylvania, 19335
Study site
Doylestown, Pennsylvania, 18901
Study site
Duluth, Minnesota, 55802
Study site
Duluth, Minnesota, 55805
Study site
Durham, North Carolina, 27704
Study site
Durham, North Carolina, 27710
Study site
East Bridgewater, Massachusetts, 02333
Study site
East Orange, New Jersey, 07018
Study site
Easton, Pennsylvania, 18042
Study site
Edgewater, New Jersey, 07020
Study site
Elizabeth, Florida, 07202
Study site
Elizabeth City, North Carolina, 27909
Study site
Elizabethtown, Kentucky, 42701
Study site
Elkhart, Indiana, 46514
Study site
Elmer, New Jersey, 08318
Study site
Encinitas, California, 92024
Study site
Erie, Pennsylvania, 16502
Study site
Evanston, Illinois, 60202
Study site
Evansville, Indiana, 47710
Study site
Everett, Washington, 98201
Study site
Fairfield, Michigan, 45014
Study site
Falls Church, Virginia, 22042
Study site
Falls Church, Virginia, 22044
Study site
Fargo, North Dakota, 58103
Study site
Feasterville, Pennsylvania, 19053
Study site
Fishers, Indiana, 46038
Study site
Fishkill, New York, 12524
Study site
Flint, Michigan, 48504
Study site
Flint, Michigan, 48532
Study site
Flushing, New York, 11355
Study site
Fort Lauderdale, Florida, 33316
Study site
Fort Wayne, Indiana, 46805
Study site
Fort Worth, Texas, 76107
Study site
Fountain Valley, California, 92708
Study site
Franklin, Indiana, 46131
Study site
Fremont, Nebraska, 68025
Study site
Fresno, California, 93720
Study site
Fresno, California, 93721
Study site
Fullerton, California, 92835
Study site
Gainesville, Florida, 32605
Study site
Gainesville, Florida, 32608
Study site
Gainesville, Florida, 32610-0277
Study site
Galax, Virginia, 24333
Study site
Glendale, California, 91204
Study site
Glendale, California, 91206
Study site
Grand Island, Nebraska, 68803
Study site
Great Falls, Montana, 59405
Study site
Greeley, Colorado, 80631
Study site
Green Bay, Wisconsin, 54301
Study site
Green Bay, Wisconsin, 54303
Study site
Greenfield, Indiana, 46140
Study site
Greenville, New Jersey, 29605
Study site
Greer, South Carolina, 29651
Study site
Guilford, Connecticut, 06437
Study site
Gulfport, Mississippi, 39503
Study site
Gurnee, Illinois, 60031
Study site
Hackensack, New Jersey, 07601
Study site
Haddon Heights, New Jersey, 08035
Study site
Hagerstown, Maryland, 21740
Study site
Hammond, Indiana, 46320-1942
Study site
Hartford, Connecticut, 06115
Study site
Haverhill, Massachusetts, 01830
Study site
Havertown, Pennsylvania, 19083
Study site
Hawaiian Gardens, California, 90716
Study site
Hawthorne, New Jersey, 07506
Study site
Hazard, Kentucky, 41701
Study site
Hershey, Pennsylvania, 17033
Study site
Hinsdale, Illinois, 60521
Study site
Hollywood, California, 90028
Study site
Hollywood, Florida, 33021
Study site
Honolulu, Hawaii, 96813
Study site
Hopewell, Virginia, 23860
Study site
Hot Springs, Arkansas, 71913
Study site
Houston, Texas, 77005
Study site
Houston, Texas, 77030
Study site
Houston, Texas, 77070
Study site
Houston, Texas, 77090
Study site
Hudson, Florida, 34667
Study site
Humble, Texas, 77338
Study site
Hyannis, Massachusetts, 02601
Study site
Indianapolis, Indiana, 46202
Study site
Indianapolis, Indiana, 46237
Study site
Indianapolis, Indiana, 46250
Study site
Indianapolis, Indiana, 46254
Study site
Indianapolis, Indiana, 46260
Study site
Inglewood, California, 90301
Study site
Jackson, Mississippi, 39216
Study site
Jackson, Tennessee, 38301
Study site
Jacksonville, Florida, 32207
Study site
Jacksonville, Florida, 32216
Study site
Jacksonville, Florida, 32224
Study site
Jacksonville Beach, Florida, 32250
Study site
Johnson City, New York, 13790
Study site
Johnson City, Tennessee, 37604
Study site
Joliet, Illinois, 60435
Study site
Jonesboro, Arkansas, 72401
Study site
Jupiter, Florida, 33458
Study site
Kalamazoo, Michigan, 49007
Study site
Kalamazoo, Michigan, 49048
Study site
Kalispell, Montana, 59901
Study site
Kansas City, Missouri, 64111
Study site
Kettering, Ohio, 45429
Study site
Killeen, Texas, 76549
Study site
Kingsport, Tennessee, 37660
Study site
Kissimmee, Florida, 34741
Study site
Knoxville, South Dakota, 37920
Study site
Knoxville, Tennessee, 37917
Study site
Knoxville, Tennessee, 37920
Study site
La Crosse, Wisconsin, 54601-4795
Study site
La Jolla, California, 92093
Study site
La Mesa, California, 91942
Study site
Laguna Hills, California, 92653
Study site
Lake Charles, Louisiana, 70601
Study site
Lake Havasu City, Arizona, 86403
Study site
Lakeland, Florida, 33805
Study site
Lancaster, Pennsylvania, 17603
Study site
Langhorne, Pennsylvania, 19047
Study site
Lansing, Michigan, 48909
Study site
Lansing, Michigan, 48910
Study site
Las Vegas, Nevada, 89102
Study site
Las Vegas, Nevada, 89128
Study site
Layton, Utah, 84041
Study site
Lexington, Kentucky, 40503
Study site
Lexington, Kentucky, 40504
Study site
Lexington, Kentucky, 40536
Study site
Lexington, Tennessee, 38351
Study site
Libertyville, Illinois, 60048
Study site
Limerick, Pennsylvania, 19468
Study site
Lincoln, Nebraska, 68506
Study site
Linden, New Jersey, 07036
Study site
Little Rock, Arkansas, 72204
Study site
Littleton, Colorado, 80120
Study site
Liverpool, New York, 13088
Study site
Loma Linda, California, 92354
Study site
Lomita, California, 90717
Study site
Long Beach, California, 90822
Study site
Los Alamitos, California, 90720
Study site
Los Angeles, California, 90015
Study site
Los Angeles, California, 90034
Study site
Los Angeles, California, 90036
Study site
Los Angeles, California, 90048
Study site
Los Banos, California, 93635
Study site
Louisville, Kentucky, 40202
Study site
Louisville, Kentucky, 40207
Study site
Loveland, Colorado, 80538
Study site
Lubbock, Texas, 79410
Study site
Madison, Wisconsin, 53713
Study site
Madison, Wisconsin, 53715
Study site
Madison, Wisconsin, 53792
Study site
Madisonville, Kentucky, 42431
Study site
Manassas, Virginia, 20109
Study site
Manchester, New Hampshire, 03102
Study site
Mansfield, Ohio, 44827
Study site
Marianna, Florida, 32446
Study site
Marion, Ohio, 43302
Study site
Marrero, Louisiana, 70072
Study site
Marshfield, Wisconsin, 54449
Study site
Mather, California, 95655
Study site
Melbourne, Florida, 32901
Study site
Melrose Park, Illinois, 60160
Study site
Mentor, Ohio, 44060
Study site
Merrillville, Indiana, 46410
Study site
Mesa, Arizona, 85206
Study site
Metairie, Louisiana, 70006
Study site
Miami, Florida, 33136
Study site
Miami, Florida, 33137
Study site
Miami, Florida, 33186
Study site
Middletown, Ohio, 45005
Study site
Midland, Michigan, 48670
Study site
Midlothian, Virginia, 23114
Study site
Midwest City, Oklahoma, 73110
Study site
Milwaukee, Michigan, 53295
Study site
Milwaukee, Wisconsin, 53215
Study site
Milwaukee, Wisconsin, 53226
Canada69 sites
Study site
Ajax, Ontario, L1S 7K8
Study site
Brampton, Ontario, L6Z 4N5
Study site
Burlington, Ontario, L7M 4Y1
Study site
Calgary, Alberta, T2E 7C5
Study site
Cambridge, Ontario, N1R 6V6
Study site
Cambridge, Ontario, N1R 7R1
Study site
Edmonton, Alberta, T5H 3V9
Study site
Edmonton, Alberta, T6K 4C1
Study site
Gatineau, Quebec, J8Y 6S9
Study site
Granby, Quebec, J2G 8Z9
Study site
Greater Sudbury, Ontario, P3E 2N8
Study site
Greater Sudbury, Ontario, P3E 3B8
Study site
Greenfield Park, Quebec, J4V 2G8
Study site
Halifax, Nova Scotia, B3H 3A7
Study site
Hamilton, Ontario, L8L 2X2
Study site
Kingston, Ontario, K7L 5G2
Study site
Kitchener, Ontario, N2H5Z8
Study site
Kitchener, Ontario, N2M 5N4
Study site
Lachine, Quebec, H8S 2E4
Study site
Laval, Quebec, H7M 3L9
Study site
Longueuil, Quebec, J4M 2X1
Study site
Mississauga, Ontario, L5B 2P7
Study site
Moncton, New Brunswick, E1G 1A7
Study site
Montreal, Quebec, H1T 1C8
Study site
Montreal, Quebec, H1T 2M4
Study site
Montreal, Quebec, H2K 4L5
Study site
Montreal, Quebec, H2W 1T8
Study site
Montreal, Quebec, H3A 1A1
Study site
Montreal, Quebec, H3G 1A4
Study site
Montreal, Quebec, H4J 1C5
Study site
Mount Pearl, Newfoundland and Labrador, A1N 1W7
Study site
Nanaimo, British Columbia, V9R 3G9
Study site
New Westminster, British Columbia, V3L 3W4
Study site
Newmarket, Ontario, L3Y 8C3
Study site
Oshawa, Ontario, L1J 2J9
Study site
Ottawa, Ontario, K1Y 4W7
Study site
Québec, Quebec, G1J 1Z4
Study site
Québec, Quebec, G1R 2J6
Study site
Québec, Quebec, G1V 4M6
Study site
Saint Georges-de-beauce, Quebec, G5Y 4T8
Study site
Saint-Charles-Borromée, Quebec, J6E 6J2
Study site
Saint-Jérôme, Quebec, J7Z 5T3
Study site
Saint-Lambert, Quebec, J4P 2H4
Study site
Saint-Léonard, Quebec, H1S 3A9
Study site
Saskatoon, Saskatchewan, S7K 0H6
Study site
Sherbrooke, Quebec, J1H 4J6
Study site
Sherbrooke, Quebec, J1H 5N4
Study site
Sherbrooke, Quebec, J1J 2E3
Study site
St. John's, Newfoundland and Labrador, A1B 3V6
Study site
St. John's, Newfoundland and Labrador, A1E 2C2
Study site
St. John's, Newfoundland and Labrador, A1E 2E2
Study site
Ste. Foy, Quebec, G1V 4G5
Study site
Surrey, British Columbia, V3V 1Z2
Study site
Terrebonne, Quebec, J6V 2H2
Study site
Thunder Bay, Ontario, P7B 2Z3
Study site
Thunder Bay, Ontario, P7B 6V4
Study site
Toronto, Ontario, M4N 3M5
Study site
Toronto, Ontario, M5B 1W8
Study site
Toronto, Ontario, M5G 1L7
Study site
Toronto, Ontario, M9W 4L6
Study site
Trois-Rivières, Quebec, G8T 7A1
Study site
Trois-Rivières, Quebec, G8Z 4K4
Study site
Val-d'Or, Quebec, J9P 3Y1
Study site
Vancouver, British Columbia, V5Z 1M9
Study site
Vancouver, British Columbia, V6Z 1Y6
Study site
Victoria, British Columbia, V8R 4R2
Study site
Westmount, Quebec, H3Z 2M6
Study site
Winnipeg, Manitoba, R2H 2A6
Study site
Winnipeg, Manitoba, R8A 1R9
Netherlands44 sites
Study site
's-Hertogenbosch, 5223 GZ
Study site
Alkmaar, 1815 JD
Study site
Almelo, 7609 PP
Study site
Amersfoort, 3818 ES
Study site
Amstelveen, 1186 AH
Study site
Amsterdam, 1061 AE
Study site
Amsterdam, 1066 EC
Study site
Amsterdam, 1081 HV
Study site
Amsterdam, 1091 AC
Study site
Amsterdam, 1105 AZ
Study site
Arnhem, 6815 AD
Study site
Blaricum, 1261 AN
Study site
Breda, 4818 CK
Study site
Capelle AD Yssel, 2906 ZC
Study site
Delft, 2625 AD
Study site
Den Helder, 1782GZ
Study site
Deventer, 7415 CM
Study site
Eindhoven, 5623 EJ
Study site
Enschede, 7512 KZ
Study site
Goes, 4462 RA
Study site
Groningen, 9728 NZ
Study site
Haarlem, 2035 RC
Study site
Heerlen, 6419 PC
Study site
Hengelo, 7555 DL
Study site
Hilversum, 1213 HX
Study site
Hoofddorp, 2134 TM
Study site
Hoorn, 1625 HV
Study site
Leiden, 2300 RC
Study site
Leiderdorp, 2353 GA
Study site
Maastricht, 6202 AZ
Study site
Nieuwegein, 3430 EM
Study site
Nijmegen, 6532 SZ
Study site
Purmerend, 1441 RN
Study site
Rotterdam, 3045 PM
Study site
Rotterdam, 3075 EA
Study site
Rotterdam, 3083 AN
Study site
Sneek, 8601 ZK
Study site
Stadskanaal, 9501 HE
Study site
Tilburg, 5022 GC
Study site
Tilburg, 5042 AD
Study site
Utrecht, 3584 CX
Study site
Weert, 6001 BE
Study site
Zaandam, 1502 DV
Study site
Zwolle, 8011 JW
Poland41 sites
Study site
Bialystok, 15-276
Study site
Bydgoszcz, 85-435
Study site
Bydgoszcz, 85-826
Study site
Elblag, 82-300
Study site
Gdansk, 80-211
Study site
Gdynia, 81-402
Study site
Gdynia, 81-472
Study site
Grodzisk Mazowiecki, 05-825
Study site
Inowrocław, 88-100
Study site
Katowice, 40-635
Study site
Krakow, 30-069
Study site
Krakow, 31-202
Study site
Lodz, 91-425
Study site
Lodz, 93-113
Study site
Lublin, 20-089
Study site
Nowa Sól, 67-100
Study site
Płock, 09-400
Study site
Poznan, 61-833
Study site
Poznan, 61-848
Study site
Puławy, 24-100
Study site
Ruda Śląska, 41-703
Study site
Siedlce, 08-110
Study site
Sopot, 81-717
Study site
Sosnowiec, 41-200
Study site
Stalowa Wola, 37-450
Study site
Starachowice, 27-200
Study site
Świdnik, 21-040
Study site
Szczecin, 70-111
Study site
Tarnów, 33-100
Study site
Torun, 87-100
Study site
Wałbrzych, 58-309
Study site
Warsaw, 00-217
Study site
Warsaw, 02-507
Study site
Warsaw, 02-637
Study site
Warsaw, 03-242
Study site
Warsaw, 96-100
Study site
Wroclaw, 50-159
Study site
Wroclaw, 50-420
Study site
Wroclaw, 50-981
Study site
Zamość, 22-400
Study site
Zielona Góra, 65-046
Brazil39 sites
Study site
Aracaju, Sergipe, 49015400
Study site
Belo Horizonte, Minas Gerais, 30110-068
Study site
Belo Horizonte, Minas Gerais, 30140092
Study site
Belo Horizonte, Minas Gerais, 30190-081
Study site
Belo Horizonte, Minas Gerais, 30190-130
Study site
Belo Horizonte, Minas Gerais, 31110-580
Study site
Campina Grande do Sul, Paraná, 83430-000
Study site
Campinas, São Paulo, 13060-803
Study site
Campo Grande, Mato Grosso do Sul, 79070900
Study site
Curitiba, Paraná, 80220-000
Study site
Curitiba, Paraná, 80730150
Study site
Fortaleza, Ceará, 60840285
Study site
Goiânia, Goiás, 74223-130
Study site
Maceió, Alagoas, 57051500
Study site
Natal, Rio Grande do Norte, 59020-100
Study site
Olinda, Pernambuco, 53030-010
Study site
Pelotas, Rio Grande do Sul, 96015-290
Study site
Porto Alegre, Rio Grande do Sul, 90020-090
Study site
Porto Alegre, Rio Grande do Sul, 90035-003
Study site
Porto Alegre, Rio Grande do Sul, 90110-270
Study site
Porto Alegre, Rio Grande do Sul, 90610-000
Study site
Porto Alegre, Rio Grande do Sul, 90620-001
Study site
Recife, Pernambuco, 50100-060
Study site
Recife, Pernambuco, 52051-380
Study site
Ribeirão Preto, São Paulo, 14048-900
Study site
Rio de Janeiro, Rio de Janeiro, 20221903
Study site
Rio de Janeiro, Rio de Janeiro, 20551030
Study site
Rio de Janeiro, Rio de Janeiro, 22240-006
Study site
Salvador, Estado de Bahia, 40140000
Study site
Santo André, São Paulo, 9190610
Study site
Sao Jose Do Rio Preto, Santa Catarina, 15015-210
Study site
Sao Jose Do Rio Preto, Santa Catarina, 15015205
Study site
São José do Rio Preto, São Paulo, 15090-000
Study site
São Paulo, São Paulo, 01323-020
Study site
São Paulo, São Paulo, 01323-030
Study site
São Paulo, São Paulo, 04012909
Study site
São Paulo, São Paulo, 05403-000
Study site
São Paulo, São Paulo, 22793-080
Study site
Uberlândia, Minas Gerais, 38400-368
Argentina38 sites
Study site
Almirante Brown, B1846DSK
Study site
Bahía Blanca, B8000ILD
Study site
Buenos Aires, 1039
Study site
Buenos Aires, 1428
Study site
Buenos Aires, 1431
Study site
Buenos Aires, 1708
Study site
Buenos Aires, 1722
Study site
Buenos Aires, B1605DSX
Study site
Buenos Aires, B2800JIR
Study site
Buenos Aires, B7600FZN
Study site
Buenos Aires, C1426ANZ
Study site
Buenos Aires, C1437JCP
Study site
Buenos Aires
Study site
CABA, C1428DCO
Study site
Capital Federal, C1093AAS
Study site
Cipolletti, 8324
Study site
Ciudad Autonoma Bs As, C1280AEB
Study site
Ciudad Autónoma de Bs. As., C1437BZK
Study site
Córdoba, 5016
Study site
Córdoba, X5000AAC
Study site
Córdoba, X5000JHQ
Study site
Coronel Suárez, B7540GDH
Study site
Corrientes, W3400AMZ
Study site
Junín, B6000CMF
Study site
La Plata, 1725
Study site
Mar del Plata, 7600
Study site
Mar del Plata, B7600FEN
Study site
Mendoza, 5500
Study site
Quilmes, 1878
Study site
Rosario, 2000
Study site
Rosario, S2000CVD
Study site
Salta, A4406CLA
Study site
San Isidro, B1642AKG
Study site
San Justo, 1754
Study site
San Martin, 1650
Study site
San Miguel de Tucumán, 4000
Study site
San Salvador de Jujuy, Y4600ABF
Study site
Santa Fe, 3000
Germany38 sites
Study site
Bad Krozingen, 79189
Study site
Bad Rothenfelde, 49124
Study site
Bad Segeberg, 23795
Study site
Berlin, 10115
Study site
Berlin, 10117
Study site
Berlin, 10249
Study site
Berlin, 12157
Study site
Berlin, 12559
Study site
Berlin, 13353
Study site
Berlin, 14050
Study site
Bielefeld, 33604
Study site
Bochum, 44787
Study site
Bochum, 44789
Study site
Burg, 03096
Study site
Coburg, 96450
Study site
Darmstadt, 64283
Study site
Dortmund, 44137
Study site
Duisburg, 47137
Study site
Essen, 45122
Study site
Frankfurt, 65929
Study site
Frankfurt am Main, 60594
Study site
Führt, 90766
Study site
Halle, 06120
Study site
Hamburg, 20099
Study site
Heidelberg, 69120
Study site
Homburg/Saar, 66421
Study site
Langen, 63225
Study site
Limburg, 65552
Study site
Mainz, 55131
Study site
Mannheim, 68167
Study site
Mönchengladbach, 41063
Study site
Neuss, 41464
Study site
Northeim, 37154
Study site
Rüdersdorf, 15562
Study site
Ulm, 89081
Study site
Villingen-Schwenningen, 78048
Study site
Witten, 58455
Study site
Wuppertal, 42117
China36 sites
Study site
Beijing, 100020
Study site
Beijing, 100034
Study site
Beijing, 100037
Study site
Beijing, 100044
Study site
Beijing, 100088
Study site
Beijing, 100101
Study site
Beijing, 10029
Study site
Changsha, 410013
Study site
Dalian, 116027
Study site
Daqing, 163001
Study site
Guangzhou, 510120
Study site
Guangzhou
Study site
Hangzhou, 310003
Study site
Hangzhou, 310009
Study site
Hangzhou, 310016
Study site
Harbin, 150086
Study site
Jinan, 250033
Study site
Lanzhou, 730000
Study site
Lanzhou, 730030
Study site
Nanchang, 330006
Study site
Nanjing, 210029
Study site
Nanjing, 210036
Study site
Shanghai, 200003
Study site
Shanghai, 200032
Study site
Shanghai, 200065
Study site
Shanghai, 200233
Study site
Shenyang, 110004
Study site
Shenyang, 110016
Study site
Shijiazhuang, 05000
Study site
Shijiazhuang, 050082
Study site
Suzhou, 215004
Study site
Suzhou, 215006
Study site
Wenzhou, 325000
Study site
Wuhan, 430060
Study site
Wuhan, 430071
Study site
Xi'an, 710061
United Kingdom27 sites
Study site
Airdrie, ML6 0JS
Study site
Barnet, EN5 3DJ
Study site
Belfast, BT47 6SB
Study site
Birmingham, B18 7QH
Study site
Birmingham, B75 7RR
Study site
Blackpool, FY3 8NR
Study site
Bradford, BD9 6RJ
Study site
Cambridge, CB1 8RN
Study site
Chertsey, KT16 0PZ
Study site
Edinburgh, EH16 4SB
Study site
Glasgow, G11 6NK
Study site
Glasgow, G31 2ER
Study site
Glasgow, G51 4TF
Study site
Larbert, FK5 4WR
Study site
Leicester, LE3 9QP
Study site
London, E11 1NR
Study site
London, EC1M 6BQ
Study site
Luton, LU4 0DZ
Study site
Manchester, M13 9WL
Study site
Middlesbrough, TS4 3BW
Study site
Middlesex, UB1 3HW
Study site
Nottingham, NG5 1PB
Study site
Nuneaton, CV10 7DJ
Study site
Paisley, PA2 9PN
Study site
Peterborough, PE3 6DA
Study site
Stockport, SK2 7JE
Study site
Swansea, SA6 6NL
Czechia23 sites
Study site
Brno, 656 91
Study site
České Budějovice, 370 87
Study site
Chrudim, 537 25
Study site
Hradec Králové, 500 05
Study site
Jihlava, 586 01
Study site
Jindřichův Hradec, 377 38
Study site
Karlovy Vary, 36066
Study site
Kroměříž, 761 01
Study site
Náchod, 547 01
Study site
Ostrava - Fifejdy, 72880
Study site
Pardubice, 53002
Study site
Prague, 100 34
Study site
Prague, 128 08
Study site
Prague, 140 21
Study site
Prague, 150 30
Study site
Prague, 169 02
Study site
Semily, 513 31
Study site
Slaný, 274 01
Study site
Tábor, 390 03
Study site
Teplice, 415 01
Study site
Trutnov, 541 01
Study site
Zlín, 762 75
Study site
Znojmo, 669 02
France22 sites
Study site
Angers, 49033
Study site
Bron, 69677
Study site
Colmar, 68003
Study site
Dijon, 21034
Study site
Lille, 59037
Study site
Marseille, 13285
Study site
Marseille, 13385
Study site
Montfermeil, 93370
Study site
Paris, 75475
Study site
Paris, 75571
Study site
Paris, 75674
Study site
Paris, 75877
Study site
Paris, 75908
Study site
Pessac, 33604
Study site
Poitiers, 86021
Study site
Roubaix, 59056
Study site
Saint-Herblain, 44800
Study site
Strasbourg, 67010
Study site
Strasbourg, 67091
Study site
Tourcoing, 59208
Study site
Valenciennes, 59322
Study site
Vandœuvre-lès-Nancy, 54511
Israel22 sites
Study site
Afula, 18101
Study site
Beersheba, 84101
Study site
Giv‘atayim, 53583
Study site
Hadera, 38100
Study site
Haifa, 31048
Study site
Haifa, 3109601
Study site
Haifa, 31096
Study site
Haifa, 34362
Study site
Jerusalem, 91031
Study site
Jerusalem, 91120
Study site
Jerusalem, 91240
Study site
Kfar Saba, 44281
Study site
Nahariya, 22100
Study site
Nazareth, 16100
Study site
Petah Tikva, 49100
Study site
Petah Tikva, 4941492
Study site
Rehovot, 76100
Study site
Tel Aviv, 6423906
Study site
Tel Aviv, 64239
Study site
Tel HaShomer, 52661
Study site
Tiberias, 15208
Study site
Tsrifin, 70300
Italy22 sites
Study site
Bergamo, Lombardy, 24128
Study site
Carpi, Emilia-Romagna, 41012
Study site
Caserta, Campania, 81100
Study site
Castelnuovo, Tuscany, 55032
Study site
Chieti, Abruzzo, 66100
Study site
Como, Lombardy, 22020
Study site
Forlì, Emilia-Romagna, 47100
Study site
Genoa, Liguria, 16128
Study site
Milan, Lombardy, 20138
Study site
Modena, Emilia-Romagna, 41100
Study site
Naples, Campania, 80131
Study site
Novara, Piedmont, 28100
Study site
Pavia, Lombardy, 27100
Study site
Pesaro, The Marches, 61100
Study site
Piacenza, Emilia-Romagna, 29100
Study site
Rome, Lazio, 00152
Study site
Rome, Lazio, 00184
Study site
Rozzano, Lombardy, 20089
Study site
S. Bonifacio, Veneto, 37047
Study site
Treviso, Veneto, 31100
Study site
Turin, Piedmont, 10126
Study site
Udine, Friuli Venezia Giulia, 33100
Spain22 sites
Study site
Alicante, 03010
Study site
Almería, 04009
Study site
Barcelona, 08003
Study site
Figueres, Girona, 17600
Study site
Guadalajara, 19002
Study site
L'Hospitalet de Llobregat, Barcelona, 08907
Study site
Lugo, 27004
Study site
Madrid, 28006
Study site
Madrid, 28040
Study site
Madrid, 28046
Study site
Majadahonda, Madrid, 28222
Study site
Málaga, Malaga, 29010
Study site
Pamplona, Navarre, 31008
Study site
Sant Joan d'Alacant, Alicante, 3550
Study site
Santander, Cantabria, 39008
Study site
Santiago de Compostela, LA Coruña, 15706
Study site
Seville, Sevilla, 41071
Study site
Tarragona, 43007
Study site
Valencia, 46014
Study site
Valladolid, 47005
Study site
Vigo, Pontevedra, 36214
Study site
Vitoria-Gasteiz, Alava, 01006
Hungary18 sites
Study site
Baja, 6500
Study site
Békéscsaba, 5600
Study site
Budapest, 1032
Study site
Budapest, 1096
Study site
Budapest, 1106
Study site
Budapest, 1115
Study site
Budapest, 1125
Study site
Budapest, 1135
Study site
Budapest, H - 1041
Study site
Debrecen, 4032
Study site
Kalocsa, 6300
Study site
Kecskemét, 6000
Study site
Pécs, 7624
Study site
Sopron, 9400
Study site
Szeged, 6720
Study site
Székesfehérvár, 8000
Study site
Szekszárd, 7100
Study site
Zalaegerszeg, 8900
Australia16 sites
Study site
Bedford Park, South Australia, 5042
Study site
Box Hill, Victoria, 3128
Study site
Cairns, Queensland, 4870
Study site
Chermside, Queensland, 4032
Study site
Coffs Harbour, New South Wales, 2450
Study site
Concord, New South Wales, 2137
Study site
Epping, New South Wales, 3076
Study site
Garran, Australian Capital Territory, 2605
Study site
Geelong, Victoria, 3220
Study site
Joondalup, Western Australia, 6027
Study site
Kingswood, New South Wales, 2747
Study site
Milton, Queensland, 4064
Study site
Nedlands, Western Australia, 6009
Study site
Sale, Victoria, 3850
Study site
Wollongong, New South Wales, 2500
Study site
Woolloongabba, Queensland, 4102
South Korea15 sites
Study site
Busan, 602-715
Study site
Daegu, 700-712
Study site
Daegu, 705-717
Study site
Gangwon-do, 24289
Study site
Gangwon-Do, 200-704
Study site
Gwangju, 61469
Study site
Gyeonggi-do, 10380
Study site
Gyeonggi-do, 10475
Study site
Incheon, 405-760
Study site
Kyonggi-do, 411-719
Study site
Seoul, 05505
Study site
Seoul, 120-752
Study site
Seoul, 134-791
Study site
Seoul, 140-73
Study site
Seoul, 156-707
South Africa14 sites
Study site
Alberton, 1449
Study site
Bloemfontein, 9301
Study site
Boksburg, 1459
Study site
Durban, 4001
Study site
Durban, 4091
Study site
Johannesburg, 2000
Study site
Johannesburg, 2013
Study site
Johannesburg, 2157
Study site
Kuilsriver, 7580
Study site
Lyttelton, Pretoria, 0157
Study site
Panorama, 7500
Study site
Pinelands, 7405
Study site
Pretoria, 0040
Study site
Somerset West, 7130
Denmark10 sites
Study site
Frederiksberg, 2000
Study site
Hellerup, 2900
Study site
Herlev, 2730
Study site
Herning, 7400
Study site
Hillerød, 3400
Study site
København S, 2300
Study site
Køge, 4600
Study site
Kolding, 6000
Study site
Roskilde, 4000
Study site
Svendborg, 5700
Belgium9 sites
Study site
Aalst, 9300
Study site
Bruges, 8000
Study site
Brussels, 1180
Study site
Brussels, 1200
Study site
Genk, 3600
Study site
Ghent, 9000
Study site
La Louvière, 7100
Study site
Roeselare, 8800
Study site
Tienen, 3300
Slovakia9 sites
Study site
Banská Bystrica, 974 01
Study site
Bardejov, 08501
Study site
Bratislava, 813 69
Study site
Bratislava, 826 06
Study site
Dolný Kubín, 02601
Study site
Martin, 036 59
Study site
Nitra, 949 01
Study site
Rimavská Sobota, 979 01
Study site
Žilina, 012 07
New Zealand8 sites
Study site
Auckland, 1023
Study site
Auckland
Study site
Christchurch, 8011
Study site
Dunedin
Study site
Hamilton, 3240
Study site
Nelson, 7001
Study site
New Plymouth, 4620
Study site
Wellington, 6012
Puerto Rico8 sites
Study site
Aguas Buenas, 00703
Study site
Caguas, 00725
Study site
Manati, 00674
Study site
Ponce, 00716
Study site
Ponce, 00717
Study site
Rio Grande, 00745
Study site
San Juan, 00921
Study site
Toa Baja, 00949
Austria7 sites
Study site
Feldkirch, 6807
Study site
Graz, 8020
Study site
Graz, 8036
Study site
Linz, 4010
Study site
Vienna, 1090
Study site
Vienna, 1100
Study site
Vienna, 1140
Switzerland7 sites
Study site
Fribourg, 1708
Study site
Geneva, 1211
Study site
Kreuzlingen, 8280
Study site
Lucerne, 6000
Study site
Lugano, 6900
Study site
Münsterlingen, 8596
Study site
Wolhusen, 6110
Sweden5 sites
Study site
Falun, 79182
Study site
Gothenburg, 416 85
Study site
Stockholm, 11883
Study site
Stockholm, 18288
Study site
Västerås, 72189
Finland3 sites
Study site
Jyväskylä, 40620
Study site
Kotka, 48100
Study site
Kuopio, 70211
Grenada1 site
Study site
Toulouse, 31059
About this study
Official title: A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome
This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of the drug. Eligible patients in stable condition will be randomized to receive either RO4607381 600mg po or placebo po, daily, together with a background of standard medication for ACS (including aspirin, antihypertensives and statins). The anticipated time on study treatment is 2+ years, and the target sample size is 15,600 individuals.
- Conditions
- Coronary Heart Disease
- Being tested
- Dalcetrapib (RO4607381), Evidence-based medical care for Acute Coronary Syndrome, Placebo
- Medical subject headings
- Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dalcetrapib (RO4607381)Drug
600mg po daily
Evidence-based medical care for Acute Coronary SyndromeDrug
As prescribed
PlaceboDrug
po daily
| Study group | Role | What they receive |
|---|---|---|
| Dalcetrapib (RO4607381) | Experimental | Not described Receives: Drug: Dalcetrapib (RO4607381); Drug: Evidence-based medical care for Acute Coronary Syndrome |
| Placebo | Placebo comparator | Not described Receives: Drug: Evidence-based medical care for Acute Coronary Syndrome; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Cardiovascular Mortality and Morbidity
Number of cardiovascular events per patient per year
Measured: From date of randomization to first event up to 48 months
Secondary outcomes (3)
Composite Endpoint:All Cause Mortality
Measured: Throughout Study, up to 53 Months
Change From Baseline for HDL Cholesterol
Measured: At 53 Months
Adverse Events, Lab Parameters, Vital Signs, ECG
Measured: Throughout Study, up to 53 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2008 (estimated)
- Study startApr 2008
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Coronary Heart DiseaseStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 15,871 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00658515
- Sponsor's protocol ID
- NC20971
- Other IDs
- 2007-005103-18
- Status last verified
- Dec 2019
- First submitted
- 28 Mar 2008
- Last updated
- 3 Jan 2020
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Schwartz GG, Leiter LA, Ballantyne CM, Barter PJ, Black DM, Kallend D, Laghrissi-Thode F, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Preiss D, Shah PK, Tardif JC, Kittelson J. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 May;43(5):1077-1084. doi: 10.2337/dc19-2204. Epub 2020 Mar 6.
PubMed 32144166Salahuddin T, Kittelson J, Tardif JC, Shah PK, Olsson AG, Nicholls SJ, Leitersdorf E, Leiter LA, Kallend D, Black DM, Barter PJ, Ballantyne CM, Schwartz GG. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 Mar;221:60-66. doi: 10.1016/j.ahj.2019.12.003. Epub 2019 Dec 16.
PubMed 31927126Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 Feb 1;3(2):164-168. doi: 10.1001/jamacardio.2017.3833.
PubMed 29071331Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 Jan 10;6(1):e004119. doi: 10.1161/JAHA.116.004119.
PubMed 28073769Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boule M, Alem S, Gregoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rheaume E, Dube MP. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. doi: 10.1161/CIRCGENETICS.116.001405. Epub 2016 Jul 14.
PubMed 27418594Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015 Jun 2;65(21):2267-75. doi: 10.1016/j.jacc.2015.03.544.
PubMed 26022813Tardif JC, Rheaume E, Lemieux Perreault LP, Gregoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dube MP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11.
PubMed 25583994Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
PubMed 23126252Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. Epub 2012 Feb 16.
PubMed 22345126Derks M, Abt M, Parr G, Meneses-Lorente G, Young AM, Phelan M. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin Investig Drugs. 2010 Oct;19(10):1135-45. doi: 10.1517/13543784.2010.509342.
PubMed 20738227Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.
PubMed 19958854Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91. doi: 10.1016/j.amjcard.2009.02.061.
PubMed 19576325
Study at a glance
From the registry record, last updated by the sponsor on 3 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome
- ClinicalTrials.gov ID
- NCT00658515
- Acronym / sponsor ID
- NC20971
- Conditions
- Coronary Heart Disease
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15,871 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- Apr 2008
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 15 Apr 2008 (estimated)
- Results
- Posted 3 Jan 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of the drug. Eligible patients in stable condition will be randomized to receive either RO4607381 600mg po or placebo po, daily, together with a background of standard medication for ACS (including aspirin, antihypertensives and statins). The anticipated time on study treatment is 2+ years, and the target sample size is 15,600 individuals.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dalcetrapib (RO4607381) | Experimental | Drug: Dalcetrapib (RO4607381), Drug: Evidence-based medical care for Acute Coronary Syndrome |
| Placebo | Placebo comparator | Drug: Evidence-based medical care for Acute Coronary Syndrome, Drug: Placebo |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- adult patients, >=45 years of age;
- recently hospitalized for ACS;
- clinically stable;
- receiving evidence-based medical and dietary management of dyslipidemia.
Key exclusion criteria (5 listed)
- uncontrolled diabetes;
- clinically unstable;
- severe anemia;
- uncontrolled hypertension;
- concomitant treatment with any other drug raising HDL-C (eg niacin, fibrates).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dalcetrapib (RO4607381)600mg po daily | Drug | Dalcetrapib (RO4607381) |
| Evidence-based medical care for Acute Coronary SyndromeAs prescribed | Drug | Dalcetrapib (RO4607381), Placebo |
| Placebopo daily | Drug | Placebo |
Primary outcome
Incidence of Cardiovascular Mortality and Morbidity
Time frame: From date of randomization to first event up to 48 months
Number of cardiovascular events per patient per year
3 secondary outcomes
Composite Endpoint:All Cause Mortality
Time frame: Throughout Study, up to 53 Months
Change From Baseline for HDL Cholesterol
Time frame: At 53 Months
Adverse Events, Lab Parameters, Vital Signs, ECG
Time frame: Throughout Study, up to 53 Months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jan 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 32144166Schwartz GG, Leiter LA, Ballantyne CM, Barter PJ, Black DM, Kallend D, Laghrissi-Thode F, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Preiss D, Shah PK, Tardif JC, Kittelson J. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 May;43(5):1077-1084. doi: 10.2337/dc19-2204. Epub 2020 Mar 6.
- Derived from this study: PubMed 31927126Salahuddin T, Kittelson J, Tardif JC, Shah PK, Olsson AG, Nicholls SJ, Leitersdorf E, Leiter LA, Kallend D, Black DM, Barter PJ, Ballantyne CM, Schwartz GG. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 Mar;221:60-66. doi: 10.1016/j.ahj.2019.12.003. Epub 2019 Dec 16.
- Derived from this study: PubMed 29071331Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 Feb 1;3(2):164-168. doi: 10.1001/jamacardio.2017.3833.
- Derived from this study: PubMed 28073769Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 Jan 10;6(1):e004119. doi: 10.1161/JAHA.116.004119.
- Derived from this study: PubMed 27418594Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boule M, Alem S, Gregoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rheaume E, Dube MP. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. doi: 10.1161/CIRCGENETICS.116.001405. Epub 2016 Jul 14.
- Derived from this study: PubMed 26022813Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015 Jun 2;65(21):2267-75. doi: 10.1016/j.jacc.2015.03.544.
- Derived from this study: PubMed 25583994Tardif JC, Rheaume E, Lemieux Perreault LP, Gregoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dube MP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11.
- Derived from this study: PubMed 23126252Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
- Derived from this study: PubMed 22345126Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. Epub 2012 Feb 16.
- Derived from this study: PubMed 20738227Derks M, Abt M, Parr G, Meneses-Lorente G, Young AM, Phelan M. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin Investig Drugs. 2010 Oct;19(10):1135-45. doi: 10.1517/13543784.2010.509342.
- Derived from this study: PubMed 19958854Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.
- Derived from this study: PubMed 19576325Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91. doi: 10.1016/j.amjcard.2009.02.061.
Related trials for Coronary Heart Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
1,089 sites in 29 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Dalcetrapib (RO4607381) and Evidence-based medical care for Acute Coronary Syndrome in people with Coronary Heart Disease, run by Hoffmann-La Roche at 1,089 sites in 29 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1,089 sites in United States, Canada, Netherlands, Poland, Brazil and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Jan 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Cardiovascular Mortality and Morbidity (time frame: From date of randomization to first event up to 48 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00658515, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2020.